

Dear Colleague,

Meet the PHARMO team at the 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) in **Copenhagen, Denmark, August 24-28, 2022.**

We can provide you with information on **PHARMO Data** and our expertise in pharmacoepidemiology and drug outcomes research.

Let us assist you with your real-world data (RWD) studies and coordination of **European multi-database studies.**

Meet us at booth #204 or plan a meeting in advance via mail pharmo@pharmo.nl

We look forward to meeting you at ICPE!

The PHARMO Institute
WWW.PHARMO.NL

Visit our website for the complete overview of our presentations at ICPE

PHARMO Institute presents the following at ICPE

COVID-19

- Safety monitoring of COVID-19 vaccines with biannual data cuts and clinical validation of adverse events of special interest (AESIs) is feasible
- Adjustment for vaccine roll out determinants is needed to avoid spurious signals between AESIs and vaccine roll out. Causal inference studies are required to establish causality.
- Continued assessment of vaccine-associated myo-/pericarditis risk is needed, especially after the second dose

Diabetes

- Comparing diabetes care outcomes of regular care versus a particular diabetes care system
- During 2004-2020, T2D prevalence in the Netherlands more than doubled. The proportion of patients using any antidiabetic treatment increased steadily throughout the study period. Risk-factor control improved between 2004-early 2010s but then declined or stagnated.

Methodology

- Identification of Frail Older Adults Using Routine Primary Care Data: Accuracy of Four Electronically Derived Algorithms
- GP Data of the PHARMO Data Network are representative of the Dutch population regarding demographic characteristics and provided primary care regarding medication use and diagnoses

Other

- Using a novel algorithm, in the ConcePTION project to extract pregnancies
- renal and cardiovascular complications in patients with CKD, T2D and/or HF in the Netherlands.
- Incidence of Lyme Borreliosis in the Netherlands
- brodalumab safety in psoriasis patients in Europe (BRAHMS study)
- lessons learned in conducting a validation study of safety outcomes from a post-approval investigation on lung cancer in five countries

